AstraZeneca Expands Investment in Huangpu

On March 19, AstraZeneca and the Management Committee of Guangzhou Economic and Technological Development District officially signed a strategic cooperation framework agreement, announcing the construction of a Radionuclide Drug Conjugate (RDC) production and supply base in Guangzhou Development District and Huangpu District.

Guangzhou International Bio Island. Photo by Jia Zihao

The new Guangzhou base will create synergies with AstraZeneca's cell therapy base in Shanghai, enhancing localized production capacity in cutting-edge fields such as radiopharmaceuticals and cell therapy, reflecting AstraZeneca's steadfast commitment to making innovative therapies rapidly accessible to patients in China and the Asia-Pacific region.
 

Huangpu District New Drug Application Service Center. Photo by Hou Peirong

From an industry perspective, this cooperation positions Guangzhou at the forefront of the nuclear medicine sector in the global biopharmaceutical landscape. As a national-level innovation hub for the biopharmaceutical industry, Guangzhou Development District and Huangpu District are moving quickly to establish a complete industry chain spanning "R&D–clinical trials–production–application" by attracting Fortune 500 enterprises such as AstraZeneca, injecting strong momentum into the cultivation of new quality productive forces.

Biomedical Industrial Park, Sino-Singapore Guangzhou Knowledge City. Photo by Jia Zihao